FindTrial
Sign In

Prostate needle biopsy modality study

A single-center retrospective analysis of the advantages and disadvantages of three different prostate biopsy modalities

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091624
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring prostate biopsy

Interventions

Magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) cognitive fusion group:NA
Ultrasound-guided transrectal prostate biopsy group:NA
Ultrasound-guided transperineal prostate needle biopsy group:NA

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Have at least one of the following characteristics: 1. PSA>10 ng/ml; 2. Suspicious nodules of the prostate found on digital rectal examination; 3. Suspicious lesions found on prostate mpMRI, any PSA value; 4. f/tPSA 0.15 ng/ml^2, and/or PSA rise rate (PSAV) > 0.75 µg/L at PSA 4-10 ng/ml.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to anesthetic drugs; 2. Those with contraindications to prostate puncture; 3. Patients who are not the first time to puncture; 4. Patients who have undergone prostate resection and gasification, and have undergone surgery and local radiotherapy for pelvic organ tumors in the past.

Design outcomes

Primary

MeasureTime frame
Positive tumor detection rate after three prostate needle biopsy modalities;—

Secondary

MeasureTime frame
Puncture time;—

Countries

China

Contacts

Public ContactTang Yuxin

Fifth Affiliated Hospital, Sun Yat-Sen University

mmcct@126.com+86 13787318086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026